Pulmonary Hypertension Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Reata, Pharmosa, Acceleron, Bellerophon, Apeiron

September 13 04:10 2023
Pulmonary Hypertension Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Reata, Pharmosa, Acceleron, Bellerophon, Apeiron
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Pulmonary Hypertension therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Pulmonary Hypertension Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Pulmonary Hypertension Market. 

The Pulmonary Hypertension Pipeline report embraces in-depth commercial, regulatory, and Pulmonary Hypertension clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Pulmonary Hypertension drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Pulmonary Hypertension Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Pulmonary Hypertension treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Pulmonary Hypertension therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Pulmonary Hypertension companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Pulmonary Hypertension drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pulmonary Hypertension therapeutic market.

Pulmonary Hypertension Therapeutics Landscape

There is no cure for pulmonary hypertension. However, there are many different types of treatments, including, Inhaled medicine, Medicine given through the veins under the skin, Medicine to reduce swelling in the feet (diuretics), and Oxygen therapy. Currently, even with PAH-specific drug treatment, the prognosis for PAH and CTEPH patients remains poor, with mean five-year survival rates of 57%-59% and 53%-69% for PAH and inoperable CTEPH, respectively. Therefore, more insight into the pathogenesis of PAH and CTEPH is highly needed, so that new therapeutic strategies can be developed.

Recent studies have shown increased presence and activation of innate and adaptive immune cells in both PAH and CTEPH patients. Moreover, extensive biomarker research revealed that many inflammatory and immune markers correlate with the hemodynamics and/or prognosis of PAH and CTEPH patients.

There are approx. 80+ key companies developing therapies for Pulmonary Hypertension. Currently, Akaza Bioscience is leading the therapeutics market with its Pulmonary Hypertension drug candidates in the most advanced stage of clinical development.

Pulmonary Hypertension Companies Actively Working in the Therapeutic Market Include:

Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Dong-A ST/Mezzion, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, VIVUS, Respira Therapeutics, Resverlogix, Bial – Portela C S.A., Vigonvita Life Sciences, Altavant Sciences, Roche, PhaseBio Pharmaceuticals, Gossamer Bio, Reviva Biopharmaceuticals, Cereno Scientific, Attgeno, Rho Federal Systems Division, Inc., Cumberland Pharmaceuticals, AstraZeneca, Aerovate Therapeutics, Celon Pharma, Camurus, ATXA Therapeutics, Gmax Biopharma, Aerami Therapeutics, Pfizer, Aadi Biosciences, SystImmune, Claritas Pharmaceuticals, Reviva Biopharmaceuticals, Aqualung Therapeutics, Pulmokine, Recursion Pharmaceuticals, and many others.

Emerging and Marketed Pulmonary Hypertension Drugs Covered in the Report Include:

  • Ralinepag: Arena Pharmaceuticals/United Therapeutics

  • Sotatercept: Acceleron Pharma

  • Zamicastat: Bial – Portela C S.A.

  • Tocilizumab: Roche

  • AER-901: Aerami Therapeutics

  • ABI-009: Aadi Biosciences

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Pulmonary Hypertension Companies Working in the Market @


Analysis of Emerging Pulmonary Hypertension Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Pulmonary Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

Learn How the Pulmonary Hypertension Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Pulmonary Hypertension Treatment Patterns

4. Pulmonary Hypertension – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pulmonary Hypertension Late Stage Products (Phase-III)

7. Pulmonary Hypertension Mid-Stage Products (Phase-II)

8. Pulmonary Hypertension Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pulmonary Hypertension Discontinued Products

13. Pulmonary Hypertension Product Profiles

14. Major Pulmonary Hypertension Companies in the Market

15. Key Products in the Pulmonary Hypertension Therapeutics Segment

16. Dormant and Discontinued Products

17. Pulmonary Hypertension Unmet Needs

18. Pulmonary Hypertension Future Perspectives

19. Pulmonary Hypertension Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Panuveitis Market

“Panuveitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Panuveitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Panuveitis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

view more articles

About Article Author